Overview

A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia

Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
This 2 arm study will evaluate the efficacy and safety of oral Bonviva 150mg once monthly compared with placebo in post-menopausal women with osteopenia. Patients will be randomized to receive either Bonviva 150mg po monthly, or placebo monthly. The anticipated time on study treatment is 1-2 years, and the target sample size is 100-500 individuals.
Phase:
Phase 4
Details
Lead Sponsor:
Hoffmann-La Roche
Treatments:
Diphosphonates
Ibandronic Acid